Adimmune Corporation

Taiwan Stock Exchange 4142.TW

Adimmune Corporation Price to Book Ratio (P/B) on January 14, 2025: 1.66

Adimmune Corporation Price to Book Ratio (P/B) is 1.66 on January 14, 2025, a -30.60% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Adimmune Corporation 52-week high Price to Book Ratio (P/B) is 2.40 on January 15, 2024, which is 44.10% above the current Price to Book Ratio (P/B).
Adimmune Corporation 52-week low Price to Book Ratio (P/B) is 1.32 on January 07, 2025, which is -20.67% below the current Price to Book Ratio (P/B).
Adimmune Corporation average Price to Book Ratio (P/B) for the last 52 weeks is 1.94.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Taiwan Stock Exchange: 4142.TW

Adimmune Corporation

CEO	Mr. Chi-Hsien Chan
IPO Date	May 3, 2012
Location	Taiwan
Headquarters	No. 3, Tanxing Road
Employees	564
Sector	Health Care
Industries Vaccines Pharmaceuticals

Description

Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.

Key trends

Past 5 years